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Abstract
Background—A marked increase in the number of cases of Middle East respiratory syndrome 
coronavirus (MERS-CoV) infection occurred in Jeddah, Saudi Arabia, in early 2014. We evaluated 
patients with MERS-CoV infection in Jeddah to explore reasons for this increase and to assess the 
epidemiologic and clinical features of this disease.
Methods—We identified all cases of laboratory-confirmed MERS-CoV infection in Jeddah that 
were reported to the Saudi Arabian Ministry of Health from January 1 through May 16, 2014. We 
conducted telephone interviews with symptomatic patients who were not health care personnel, 
and we reviewed hospital records. We identified patients who were reported as being 
asymptomatic and interviewed them regarding a history of symptoms in the month before testing. 
Descriptive analyses were performed.
Results—Of 255 patients with laboratory-confirmed MERS-CoV infection, 93 died (case fatality 
rate, 36.5%). The median age of all patients was 45 years (interquartile range, 30 to 59), and 174 
patients (68.2%) were male. A total of 64 patients (25.1%) were reported to be asymptomatic. Of 
the 191 symptomatic patients, 40 (20.9%) were health care personnel. Among the 151 
symptomatic patients who were not health care personnel, 112 (74.2%) had data that could be 
assessed, and 109 (97.3%) of these patients had had contact with a health care facility, a person 
with a confirmed case of MERS-CoV infection, or someone with severe respiratory illness in the 
14 days before the onset of illness. The remaining 3 patients (2.7%) reported no such contacts. Of 
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the 64 patients who had been reported as asymptomatic, 33 (52%) were interviewed, and 26 of 
these 33 (79%) reported at least one symptom that was consistent with a viral respiratory illness.
Conclusions—The majority of patients in the Jeddah MERS-CoV outbreak had contact with a 
health care facility, other patients, or both. This highlights the role of health care–associated 
transmission. (Supported by the Ministry of Health, Saudi Arabia, and by the U.S. Centers for 
Disease Control and Prevention.)
The Middle East respiratory syndrome coronavirus (MERS-CoV), an emerging novel 
betacoronavirus belonging to lineage C, is known to cause severe acute respiratory illness in 
humans. From the time the disease was first identified in 2012, mortality among patients 
with laboratory-confirmed infection has been reported to be approximately 30 to 40%.1,2 As 
of this writing, cases have been linked to seven countries in or near the Arabian Peninsula, 
and the majority of reported cases have been from Saudi Arabia.3,4
A zoonotic origin of MERS-CoV has been presumed on the basis of evidence to date. The 
reservoir, mechanism of transmission, and risk factors for transmission resulting in primary 
cases of infection remain elusive,5 although increasing evidence suggests that dromedary 
camels may be able to transmit the virus to humans through close contact.6-8 Infected camels 
may have mild, self-limited respiratory signs or inapparent infection.6,9 Primary cases of 
MERS-CoV infection that are probably associated with zoonotic exposures have been 
documented in community settings and can result in limited secondary transmission in 
households.10 Secondary transmission in health care settings, which also has been 
documented, has resulted in large outbreaks.11,12 Data on risk factors for transmission in 
households and health care settings are lacking.
Beginning in mid-March 2014, an increase in reported cases of MERS-CoV infection in 
Jeddah, Saudi Arabia, heightened international concern3,13 about the potential for global 
transmission of this virus.14 Amid intense speculation regarding the cause of the sudden 
increase in cases, several hypotheses emerged, including, either alone or in combination, 
genomic changes resulting in increased transmissibility of the virus, an unidentified 
seasonality component, an increase in testing to detect MERS-CoV infection, an increase in 
primary cases in the community as a result of changes in contacts between humans and 
potential animal reservoirs, an increase in cases because of sustained transmission in the 
community (unrelated to health care exposures), and health care–associated amplification. 
Subsequently, a laboratory-based study indicated that the outbreak was not associated with 
changes in the virus, and the investigators postulated a predominance of human-to-human 
transmission in Jeddah as an explanation.15
On May 10, 2014, the Saudi Arabian Ministry of Health, with assistance from the U.S. 
Centers for Disease Control and Prevention (CDC), began an investigation to determine the 
reasons for the increase in cases of MERS-CoV infection. Our primary objectives were to 
identify the cause of the increase in reported cases by characterizing the possible sources of 
exposure and to define the epidemiologic and clinical features of patients with the disease. 
Because data are lacking regarding asymptomatic patients with MERS-CoV infection, our 
secondary objective was to further characterize asymptomatic patients within our cohort.
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Methods
Patients and Study Oversight
All patients from the Jeddah region who were reported to have laboratory-confirmed MERS-
CoV infection between January 1 and May 16, 2014, were identified. In Saudi Arabia, 
before May 13, 2014, a person was considered to have a confirmed case of MERS-CoV 
infection if there was laboratory confirmation of MERS-CoV infection on the basis of a 
positive real-time reverse-tran-scriptase–polymerase-chain-reaction (RT-PCR) assay 
targeting two genes — the E gene and open-reading frame gene 1a. Persons with confirmed 
infection included reportedly asymptomatic persons who were identified by contact tracing, 
post-exposure screening of health care personnel, or both. The case definition was revised on 
May 13, 2014, after which a person with a confirmed case of MERS-CoV infection was 
defined as a person with laboratory confirmation as noted above and clinical or radiologic 
evidence consistent with the infection.16-18
In Saudi Arabia, real-time RT-PCR testing for MERS-CoV is performed at five Saudi 
Arabian Ministry of Health regional laboratories, one of which is located in Jeddah. In 
addition, at least three hospitals in Jeddah independently perform real-time RT-PCR testing 
for MERS-CoV in hospitalized patients with suspected infection.
We obtained a list of patients with laboratory-confirmed MERS-CoV cases from the 
Ministry of Health regional laboratory in Jeddah. We also obtained case information from 
the Communicable Diseases Control Department of the Ministry of Health in Riyadh, the 
Jeddah Health Affairs Directorate, and from local hospitals in Jeddah that were identified 
through these two aforementioned sources as having patients with laboratory-confirmed 
MERS-CoV infection.
Since this investigation was part of a public health response, it was not considered by the 
CDC and the Saudi Arabian Ministry of Health to be research that was subject to review by 
an institutional review board. Written informed consent was not required.
Possible Sources of Exposure
In order to identify possible sources of exposure among symptomatic patients, we first 
categorized all patients according to health status (symptomatic or asymptomatic) and 
employment status (health care personnel or not health care personnel) as coded by the 
Ministry of Health or admitting hospitals. We then attempted to contact the symptomatic 
patients who were not health care personnel at least four times by telephone. We obtained 
oral informed consent from these patients, and we conducted telephone interviews in Arabic 
or English. Proxies (i.e., the closest relative or friend) were interviewed if patients were 
deceased. Interviews were conducted from May 12 through June 9, 2014. Patients or their 
proxies were asked about demographic characteristics, occupation, underlying medical 
conditions, the clinical course of the infection, and exposure.
In addition, available hospital medical records were reviewed to characterize potential 
exposures and verify information obtained from telephone interviews. We categorized 
patients according to whether they had worked at, been admitted to, or visited a health care 
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facility, as well as according to whether they reported contact with a patient with confirmed 
MERS-CoV infection or someone admitted to the hospital with severe respiratory illness of 
unknown cause during the 14 days before the onset of illness. These criteria addressed 
potential secondary exposures as specified in the revised World Health Organization (WHO) 
case–control protocol for assessment of potential risk factors for primary MERS-CoV 
infection.19
In patients in whom secondary exposures were identified, we did not collect information 
about primary exposure (e.g., contact with animals). The dates of onset of illness were 
extracted from hospital charts, telephone interviews, or Ministry of Health case lists. For 
patients in whom the date of onset of illness was unclear, we first used the date of onset of 
MERS-CoV–related symptoms.
Next, if that date was not available, we used the date of clinical deterioration (e.g., 
admission to an intensive care unit [ICU]), and finally, if neither of those dates were 
available, we used the date of testing for MERS-CoV. When information about exposure 
before the onset of illness was available, we characterized admissions to a health care 
facility according to the primary diagnosis and we characterized visits to a health care 
facility according to type (emergency or outpatient visit, or visits to hospitalized friends or 
family). Symptomatic patients who were not health care workers and who had none of the 
aforementioned exposures were considered to be potential primary cases.
Signs and Symptoms in Patients Reported to Have Been Asymptomatic
We conducted a telephone survey from May 26 through June 8, 2014, of patients who had 
been coded by the Ministry of Health and reported to the WHO as being asymptomatic. At 
least four attempts were made to contact patients with available telephone numbers. We 
obtained oral informed consent from these patients, and we conducted the telephone 
interviews in Arabic or English.
We sought to determine whether, in fact, any of the following signs or symptoms had been 
present during the 1 month before PCR testing to detect MERS-CoV (the period that was 
consistent with the presumed duration of viral shedding)20: cough, shortness of breath, 
rhinorrhea, sore throat, hemoptysis, fever, chills, muscle pain, abdominal pain, nausea, 
vomiting, diarrhea, rash, fatigue, chest pain, headache, night sweats, or other symptoms. The 
interview questions pertained to the patients’ demographic characteristics, occupation, and 
underlying medical conditions, as well as the clinical course of the infection, the reason for 
testing to detect MERS-CoV, and the history of defined symptoms. Patients were then 
characterized according to the presence or absence of symptoms and, among patients who 
were determined to have had symptoms, according to the type of symptoms.
Statistical Analysis
Descriptive analyses were performed for the following groups: all patients, all symptomatic 
patients who were not health care personnel, and asymptomatic patients. Results were 
reported as frequencies and proportions for categorical variables and as median values and 
interquartile ranges for continuous variables. In addition, the chi-square test, Fisher's exact 
test, and the F-test were used to compare prespecified subgroups of symptomatic patients 
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(those who were not available for the assessment of potential exposure to MERS-CoV vs. 
those who were available for that assessment) and of asymptomatic patients (those who 
responded to the telephone survey vs. those who did not respond). A P value of less than 
0.05 was considered to indicate statistical significance. All analyses were conducted with the 
use of SAS software, version 9.3 (SAS Institute).
Results
We identified 255 patients in Jeddah who had laboratory-confirmed MERS-CoV infection. 
The median age was 45 years (interquartile range, 30 to 59). A total of 174 patients (68.2%) 
were male, 78 (30.6%) were health care personnel, 140 (54.9%) were from Saudi Arabia, 93 
(36.5%) were admitted to an ICU, and 93 died (case-fatality rate, 36.5%) (Table 1).
Figure 1 shows an epidemic curve according to the date of onset of illness in symptomatic 
patients and according to the date of the test for MERS-CoV infection in asymptomatic 
patients. Of the 255 patients, 64 (25.1%) were reported to be asymptomatic, of whom 41 
(64%) were health care personnel (Fig. 2). Of the 191 symptomatic patients, 40 (20.9%) 
were health care personnel. Among the 151 symptomatic patients who were not health care 
personnel, the median age was 54 years (interquartile range, 37 to 64), 118 (78.1%) were 
men, 100 (66.2%) were from Saudi Arabia, and 89 died (58.9%) (Table 1).
Of the 151 symptomatic patients who were not health care personnel, we obtained data on 
130 (86.1%), by telephone interview (89 [58.9% ]), review of medical charts (122 [80.8% ]), 
or both (81 [53.6% ]). The inability to reach a patient by telephone was attributable to a lack 
of an available phone number or four unsuccessful calling attempts. Among the 130 
symptomatic patients who were not health care personnel and who were called or had 
medical charts reviewed, exposures before the onset of illness could be assessed in 112 
(86.2%). Exposures before the onset of illness were not assessed in 18 patients owing to 
insufficient medical history (Fig. 2). Patients who were contacted by telephone and for 
whom potential exposures were assessed were significantly more likely to have been 
admitted to an ICU than those for whom we could not assess exposure (P<0.001) (Table 1). 
Otherwise, the characteristics that were evaluated were similar in the two groups.
Of the 112 patients with data that could be assessed, 109 (97.3%) had one or more of the 
following types of secondary exposures during the 14 days before the onset of symptoms: 
admission to a health care facility (37 patients [33.9% ]), visits to a health care facility as a 
patient (68 patients [62.4% ]), contact with a patient who had confirmed MERS-CoV 
infection (22 patients [20.2% ]), or contact with someone with a severe respiratory illness of 
unknown cause (4 patients [3.7% ]) (Table 2). Only 3 of the 112 symptomatic patients who 
were not health care personnel (2.7%) reported no secondary exposures. Overall, 98 patients 
(87.5%) had exposure to a health care facility and 14 (12.5%) did not.
Among the 68 visits to a health care facility during the 14 days preceding the onset of 
illness, 35 (51%) were related to renal dialysis. Eighteen patients visited family members or 
friends in a health care facility, and 11 of these patients reported that this visitation was their 
only health care–related exposure. Among the 37 admissions to a health care facility during 
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the 14 days preceding the onset of illness, the median interval between admission and the 
onset of MERS-CoV symptoms was 11 days (interquartile range, 7 to 23).
Of the 64 patients who were originally identified as being asymptomatic, 33 (52%) were 
available for the telephone survey. There were no significant differences in demographic 
characteristics between the 33 patients who responded to the telephone survey and the 31 
patients who did not respond. Table 3 lists the demographic characteristics of these patients, 
reasons for testing, and symptoms reported. Of note, 73% of the patients were health care 
personnel. Twenty-six of the 33 asymptomatic patients who were reached by telephone 
(79%) reported at least one symptom in the month before testing, and 23 (70%) reported 
more than one symptom. Unexpectedly, 12 of the 33 patients surveyed (36%) reported the 
presence of signs and symptoms as the reason for MERS-CoV testing, even though they had 
been identified as being asymptomatic (Table 3).
Discussion
The outbreak of MERS-CoV infections in Jeddah raised international concern and led to 
widespread speculation regarding possible causes. We found that the marked increase in the 
number of patients with MERS-CoV infection in Jeddah could be explained by secondary 
human-to-human transmission and amplification in health care facilities, rather than by a 
sudden increase in primary cases in the community. We determined that the vast majority of 
patients with reported MERS-CoV infection in the Jeddah region from January 1 through 
May 16, 2014, had potential exposure to other patients with MERS-CoV infection, mostly in 
health care settings. We could not identify these exposures in 3 of 112 symptomatic patients 
who were not health care personnel (2.7%) and who had data that could be assessed. Efforts 
to identify risk factors for community transmission, including exposure to animals, are 
ongoing in Saudi Arabia and were not part of this investigation. We provide a further 
description of reportedly asymptomatic MERS-CoV patients, the majority of whom were 
health care personnel in clinical settings. We were able to elicit a history of symptoms in a 
majority of patients, and a substantial proportion reported the presence of symptoms as the 
reason for testing for MERS-CoV infection. These findings warrant further investigation.
Our study had several limitations. On the basis of the epidemiology of MERS-CoV to date, 
we considered the risk of MERS-CoV transmission to be higher in health care facilities than 
in the community. We thus designated cases as being potentially health care–associated if we 
could document an exposure to a health care setting or a patient with MERS-CoV infection 
during the 14 days before the onset of illness.19 Given this, it is possible that among patients 
with frequent visits to health care facilities, some cases that we designated as health care–
associated could have been primary cases. In addition, because MERS-CoV testing is 
ordered at the discretion of the treating health care personnel, the decision to test could be 
biased toward certain features such as access to health care, demographic characteristics, or 
underlying disease. Second, for patients in whom the onset of illness was unclear, we used 
the date of MERS-CoV testing, the date of clinical deterioration (e.g., admission to an ICU), 
or the date of onset of MERS-CoV–related symptoms. Although the onset of illness was 
unclear in a small number of patients, these patients had frequent health care–related 
exposures that could have provided multiple opportunities for MERS-CoV transmission.
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Third, some symptomatic patients were not reached by telephone, although assessed 
variables indicated that these patients were similar to those who were reached (Table 1). In 
addition, although medical histories were supplemented by hospital chart review in most 
cases, poor recall may have limited the accuracy of some responses. Fourth, asymptomatic 
patients were identified through a variety of methods (e.g., investigation of contacts and 
screening of health care workers) and not through routine surveillance. Among health care 
personnel, the decision to seek testing may have been influenced by knowledge or 
perception of high-risk exposures. However, because we restricted our analysis of secondary 
exposures to persons who were not health care personnel, this is unlikely to have affected 
our results. Finally, no controls were enrolled for comparison with cases; therefore, we could 
not assess the frequency of respiratory symptoms or exposure to health care facilities in this 
population.
The large proportion of reported cases associated with exposure to health care facilities 
highlights the importance of implementation of infection-control practices to limit 
transmission. Our results show a wide range of clinical presentations associated with MERS-
CoV in various locations within health care facilities. These findings underscore the need to 
strengthen infection prevention and control practices throughout health care facilities, 
including early recognition and care of patients who are potentially infected with MERS-
CoV and who present with mild disease. Saudi Arabia has recently revised its Ministry of 
Health MERS-CoV surveillance case definitions and infection-control guidance.18 This 
revision has been accompanied by intensive efforts to improve case detection, testing, and 
reporting. Efforts are ongoing to strengthen infection-control practices throughout Saudi 
Arabia.
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Figure 1. Laboratory-Confirmed Cases of MERS-CoV Infection
The date of onset of symptoms is shown for symptomatic patients, and the date of testing for 
MERS-CoV is shown for asymptomatic patients.
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Figure 2. Characteristics of Patients with Confirmed MERS-CoV Infection
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 m
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Table 2
Types of Secondary Exposure to MERS-CoV in 109 Patients within 14 days before Onset of Symptoms.*
Source of Exposure No. of Patients (%)
Admission to a health care facility for treatment 37 (34)
Cardiopulmonary disease† 9 (8)
Surgery 5 (5)
Gastrointestinal disease‡ 4 (4)
Bloodstream infection 3 (3)
Endocrine disease 3 (3)
Neurologic disease 3 (3)
Cancer or immunosuppression 3 (3)
Skin and soft-tissue infection 3 (3)
Renal disease 2 (2)
Vascular disease 2 (2)
Outpatient visit to a health care facility for treatment 68 (62)
Emergency department
 Cardiovascular disease 3 (3)
 Gastrointestinal disease 3 (3)
 Trauma 2 (2)
Outpatient facility
 Renal dialysis 35 (32)
 Endocrine disease 2 (2)
 Cancer 2 (2)
 Cardiovascular disease 1 (1)
 Prenatal visit 1 (1)
 General clinic visit 1 (1)
Visit to a patient at a health care facility 18 (17)
Potential case contact not related to exposure at a health care facility 26 (24)
Contact with a patient with a confirmed MERS-CoV infection 22 (20)
Contact with a person with a severe respiratory illness of unknown cause 4 (4)
*
Patients may have had more than one type of exposure. No secondary exposures were detected in 3 of 112 symptomatic patients who were not 
health care personnel (2.7%) and who had confirmed infection.
†Admissions related to the cardiopulmonary system included congestive heart failure, chronic obstructive pulmonary disease, cardiomyopathy, 
myocardial infarction, mitral stenosis, chest pain, and hypotension.
‡Admissions related to the gastrointestinal system included intestinal hemorrhage, perforated intestine, hepatic encephalopathy, and anorexia.
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Table 3
Demographic Characteristics, Reasons for Testing, and Signs and Symptoms Reported within 1 Month before 
Testing among 33 Patients Initially Reported as Being Asymptomatic.
Characteristic All Patients R (N = 33) eported No Symptoms (N = 7) Reported Symptoms (N = 26)
Demographic characteristics and medical history
 Age — yr
   Median 35 29 36
   Interquartile range* 27-51 28-37 26-52
 Male sex — no. (%) 20 (61) 2 (29) 18 (69)
 Saudi Arabian — no. (%) 14 (42) 3 (43) 11 (42)
 Health care personnel — no. (%) 24 (73) 6 (86) 18 (69)
 Underlying illness — no. (%) 14 (42) 1 (14) 13 (50)
Reason for test — no. (%)
 Contact investigation 5 (15) 3 (43) 2 (8)
 Screening of health care worker 15 (45) 4 (57) 11 (46)
 Presence of signs and symptoms 12 (36) 0 12 (46)
Signs and symptoms — no. (%)
 Fever 16 (48) NA 16 (62)
 Cough 13 (39) NA 13 (50)
 Shortness of breath 11 (33) NA 11 (42)
 Fatigue 9 (27) NA 9 (35)
 Nausea and vomiting 6 (18) NA 6 (23)
 Rhinorrhea 5 (15) NA 5 (19)
 Sore throat 5 (15) NA 5 (19)
 Diarrhea 4 (12) NA 4 (15)
 Chills 3 (9) NA 3 (12)
 Muscle pain 3 (9) NA 3 (12)
 Headache 3 (9) NA 3 (12)
 Chest pain 2 (6) NA 2 (8)
 Loss of appetite 2 (6) NA 2 (8)
 Abdominal pain 1 (3) NA 1 (4)
 Conjunctivitis 1 (3) NA 1 (4)
 Night sweats 1 (3) NA 1 (4)
 Rash 1 (3) NA 1 (4)
 More than one sign or symptom 23 (70) NA 23 (88)
 Fever, cough, and shortness of breath 7 (21) NA 7 (27)
*
The range for all patients was 1 to 71 years, for patients who reported no symptoms 26 to 43 years, and for patients who reported symptoms 1 to 
71 years.
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